1310460-70-8

Basic information

• Product Name: (1S)-2-(benzyloxy)-1-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol
• Synonyms: (1S)-2-(benzyloxy)-1-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol
• CAS NO: 1310460-70-8
• Molecular Weight: 252.31
• Mol File: 1310460-70-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (1S)-2-(benzyloxy)-1-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-2-(benzyloxy)-1-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol(1310460-70-8)
• EPA Substance Registry System: (1S)-2-(benzyloxy)-1-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol(1310460-70-8)

Safety Data

• Hazardous Substances Data: 1310460-70-8(Hazardous Substances Data)

Upstream product

• 91274-05-4 (2S,3S)-1,2-O-isopropylidene-1,2,3,4-tetrol 
• 100-39-0 benzyl bromide 
• 114184-94-0 ethyl (R)-2-[(4'R)-2',2'-dimethyl-1,3-dioxolan-4'-yl]-2-hydroxyacetate 
• 114184-97-3 (S)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol 

Downstream Products

• 1310460-66-2 3,4-anhydro-1-O-benzyl-2-O-methyl-D-erythritol 
• 1310460-67-3 3,4-anhydro-1-O-benzyl-2-O-ethyl-D-erythritol 
• 1310460-68-4 3,4-anhydro-1-O-benzyl-2-O-(tridec-1-yl)-d-erythritol 
• 1310460-59-3 2,3,5-tri-O-benzyl-1,4-[(R)-[1-O-benzyl-4-deoxy-2-O-methyl-D-erythritol-4-yl]episulfoniumylidene]-1,4-dideoxy-D-arabitol chloride 
• 1310460-63-9 1-O-benzyl-2-O-methyl-D-erythritol 
• 1310460-62-8 1-O-benzyl-2-O-(tridec-1-yl)-3,4-O-isopropylidene-D-erythritol 
• 1310460-61-7 1-O-benzyl-2-O-ethyl-3,4-O-isopropylidene-D-erythritol 
• 1310460-60-6 1-O-benzyl-2-O-methyl-3,4-O-isopropylidene-D-erythritol 
• 1392478-90-8 2,3,5-tri-O-benzyl-1,4-{(R)-[1-O-benzyl-4-deoxy-3-Oneopentyl-D-erythritol-4-yl]episulfoniumylidene}-1,4-dideoxy-D-arabinitol chloride 
• 1392478-87-3 2,3,5-tri-O-benzyl-1,4-[(R)-[1-O-benzyl-4-deoxy-2-O-(1-pentyl)-D-erythritol-4-yl]episulfoniumylidene]-1,4-dideoxy-D-arabitol chloride 

Relevant articles and documents

Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine ‘Salacia’

Using an in silico method, seven analogs bearing hydrophobic substituents (8a: Me, 8b: Et, 8c: n-Pent, 8d: n-Hept, 8e: n-Tridec, 8f: isoBu and 8g: neoPent) at the 3′-O-position in salacinol (1), a highly potent natural α-glucosidase inhibitor from Ayurvedic traditional medicine ‘Salacia’, were designed and synthesized. In order to verify the computational SAR assessments, their α-glucosidase inhibitory activities were evaluated in vitro. All analogs (8a–8g) exhibited an equal or considerably higher level of inhibitory activity against rat small intestinal α-glucosidases compared with the original sulfonate (1), and were as potent as or higher in potency than the clinically used anti-diabetics, voglibose, acarbose or miglitol. Their activities against human maltase exhibited good relationships to the results obtained with enzymes of rat origin. Among the designed compounds, the one with a 3′-O-neopentyl moiety (8g) was most potent, with an approximately ten fold increase in activity against human maltase compared to 1.

CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME

Provided is a novel cyclic sulfonium salt compound which is useful for the prevention or treatment of diabetes and the like. The present invention relates to a novel cyclic sulfonium salt compound represented by general formula (I) or (II), an isomer or solvate of the compound, or a pharmaceutically acceptable salt of the compound or the isomer or solvate. The present invention also relates to an α-glucosidase inhibitor, a pharmaceutical composition for preventing or treating diabetes, and an anti-diabetes food, each of which comprises the compound represented by general formula (I) or (II) and the like.